LivaNova Raises 2026 Guidance After Third-Quarter Revenue Growth
LivaNova reported Q3 2026 revenue of $393.1M, up 9.9% YoY, and adjusted EPS of $1.23. GAAP EPS was $0.11, with net income of $34.3M. The company raised full-year 2026 revenue growth guidance to 9-10% and adjusted EPS to $4.40-$4.50. Growth was driven by cardiopulmonary and neuromodulation segments, with new manufacturing lines and positive clinical study results.
How this was made
The 30-second read
Why it matters
The guidance lift is a fresh, material development that can influence trading decisions.
Market read
Guidance raise is likely to attract buying interest in LIVN and may lift related med‑tech stocks.
What to watch
Potential regulatory or reimbursement risks for new CPT codes could temper upside.
Background
LivaNova reported Q3 2026 results with revenue up 9.9% YoY and announced higher full‑year guidance.
Ticker impact
LivaNova raised full-year 2026 revenue growth to 9‑10% and adjusted EPS guidance to $4.40‑$4.50, the first report of the updated guidance.
likely upward pressure as investors price in higher revenue and earnings expectations
The company disclosed higher guidance for the first time, which typically lifts the stock.
Market effects
Positive for the medical device sector as a peer shows stronger demand for consumables and neuromodulation products.
May boost European and U.S. med‑tech equities that trade alongside LivaNova.
Limited to healthcare investors; no broad market effect.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyLivaNova PLC
Medical device manufacturer listed on NYSE under ticker LIVN.
